From company formation to Phase II clinical trials, we orchestrate the strategic expertise that transforms biotech concepts into fundable realities. Your vision, our experience, integrated execution. Your roadmap to funded, executable progress.
Alacrita's Enterprise Development practice supports life‑science ventures from first capital planning through later development milestones.
We combine market research, scientific insight, and operating experience to craft investor‑ready business plans, refine fundraising narratives, provide interim C‑suite leadership, shape platform‑technology strategy, and, when needed, advise on later‑stage planning. Because capital strategy, development execution, and downstream commercial considerations are connected, our integrated approach keeps decisions aligned and prevents the hand‑offs that slow progress. Drawing on decades of real‑world industry experience, we deliver evidence‑based strategies that give investors the clarity they need to commit capital.
Whether you are sizing an addressable market for a Seed round, mapping the milestones needed for Series B, steering a virtual biotech through a leadership gap, or pressure testing how today's choices affect future market entry, we deliver the clarity and confidence your team needs to move forward. Our senior consultants have all held operating and leadership roles in the industry - we've been where you are. This firsthand experience, combined with our integrated approach, ensures guidance that is practical, timely, and actionable.
A sound strategy is essential to healthcare investors at all stages of corporate development.
Learn more
Helping you advance programs by providing seasoned operators ready to step in, when you're not in position to permanently hire.
Learn more
Strategic guidance for platform technology developers making critical decisions about partnerships, business models, indication prioritization and regulatory pathways.
For biotechs considering the "go-it-alone" approach, we provide strategic mapping of the budget, resources, and activities required to commercialize a pipeline product. While most biotechs will ultimately partner with commercial-stage pharma, we help early-stage companies understand the feasibility, resource requirements, and timeline to launch in parallel with their clinical-regulatory development. This is strategic planning, not executional support, that provides you a clear view down the road to inform critical decisions during early clinical stages.
Learn more
Evidence-based strategies backed by real-world experience
Expert guidance exactly when and where you need it
Strategic foresight that protects long-term value
That continuity is increasingly what investors expect and what single focus firms often leave as a gap.
Alacrita's core team draws on a carefully curated network of more than 350 senior consultants assembled over the past fifteen years. These consultants average 20 years of experience across clinical, regulatory, CMC, commercial, and business development functions, spanning every major therapy area and product modality. Importantly, Alacrita maintains oversight of every engagement - we don't simply make introductions. Our core team, all with deep industry experience, orchestrates the right expertise at the right time, ensuring seamless integration and strategic continuity throughout your project.
The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.
Remember:
Speak with us about our pharma & biotech consulting services.
Alacrita, UK, Europe & Asia
2 Royal College St
London, UK
NW1 0NH
Registered in England & Wales.
No. 10530608
Alacrita, US
One Broadway
Floor 14
Cambridge, MA 02142
Registered in Massachusetts.
© 2009 - 2025 Alacrita Holdings Limited
